[go: up one dir, main page]

WO2004020595A8 - Novel human polypeptides encoded by polynucleotides - Google Patents

Novel human polypeptides encoded by polynucleotides

Info

Publication number
WO2004020595A8
WO2004020595A8 PCT/US2003/027107 US0327107W WO2004020595A8 WO 2004020595 A8 WO2004020595 A8 WO 2004020595A8 US 0327107 W US0327107 W US 0327107W WO 2004020595 A8 WO2004020595 A8 WO 2004020595A8
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotides
polypeptides encoded
novel human
human polypeptides
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/027107
Other languages
French (fr)
Other versions
WO2004020595A3 (en
WO2004020595A2 (en
Inventor
Lewis T Williams
Keting Chu
Ernestine Lee
Kevin Hestir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dnaform KK
RIKEN
Five Prime Therapeutics Inc
Original Assignee
Dnaform KK
RIKEN
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnaform KK, RIKEN, Five Prime Therapeutics Inc filed Critical Dnaform KK
Priority to AU2003274935A priority Critical patent/AU2003274935A1/en
Publication of WO2004020595A2 publication Critical patent/WO2004020595A2/en
Publication of WO2004020595A8 publication Critical patent/WO2004020595A8/en
Anticipated expiration legal-status Critical
Publication of WO2004020595A3 publication Critical patent/WO2004020595A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides novel polynucleotides, related polypeptides, related nucleic acid and polypeptide compositions, and related modulators, such as antibodies and small molecule modulators. The compositions of the invention are useful' in treating proliferative disorders, e.g., cancers, and inflammatory, immune, bacterial, and viral disorders.
PCT/US2003/027107 2002-08-29 2003-08-28 Novel human polypeptides encoded by polynucleotides Ceased WO2004020595A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003274935A AU2003274935A1 (en) 2002-08-29 2003-08-28 Novel human polypeptides encoded by polynucleotides

Applications Claiming Priority (68)

Application Number Priority Date Filing Date Title
US40666602P 2002-08-29 2002-08-29
US40665502P 2002-08-29 2002-08-29
US40657602P 2002-08-29 2002-08-29
US40661602P 2002-08-29 2002-08-29
US40664002P 2002-08-29 2002-08-29
US40661102P 2002-08-29 2002-08-29
US40661202P 2002-08-29 2002-08-29
US60/406,611 2002-08-29
US60/406,666 2002-08-29
US60/406,655 2002-08-29
US60/406,576 2002-08-29
US60/406,616 2002-08-29
US60/406,612 2002-08-29
US60/406,640 2002-08-29
US41096202P 2002-09-17 2002-09-17
US41095102P 2002-09-17 2002-09-17
US41108202P 2002-09-17 2002-09-17
US41101902P 2002-09-17 2002-09-17
US41111102P 2002-09-17 2002-09-17
US41094602P 2002-09-17 2002-09-17
US41096002P 2002-09-17 2002-09-17
US41105202P 2002-09-17 2002-09-17
US41095302P 2002-09-17 2002-09-17
US41102402P 2002-09-17 2002-09-17
US41095702P 2002-09-17 2002-09-17
US41102202P 2002-09-17 2002-09-17
US41104602P 2002-09-17 2002-09-17
US41103702P 2002-09-17 2002-09-17
US60/410,960 2002-09-17
US60/411,082 2002-09-17
US60/410,962 2002-09-17
US60/411,052 2002-09-17
US60/410,957 2002-09-17
US60/411,022 2002-09-17
US60/410,946 2002-09-17
US60/411,046 2002-09-17
US60/411,019 2002-09-17
US60/410,953 2002-09-17
US60/411,037 2002-09-17
US60/410,951 2002-09-17
US60/411,111 2002-09-17
US60/411,024 2002-09-17
US46370003P 2003-04-18 2003-04-18
US46373203P 2003-04-18 2003-04-18
US60/463,700 2003-04-18
US60/463,732 2003-04-18
US46723003P 2003-05-02 2003-05-02
US46720303P 2003-05-02 2003-05-02
US60/467,230 2003-05-02
US60/467,203 2003-05-02
US47130603P 2003-05-19 2003-05-19
US60,471,306 2003-05-19
US47242003P 2003-05-22 2003-05-22
US60/472,420 2003-05-22
US47660903P 2003-06-09 2003-06-09
US60/476,609 2003-06-09
US48532503P 2003-07-08 2003-07-08
US48522303P 2003-07-08 2003-07-08
US60/485,223 2003-07-08
US60/485,325 2003-07-08
US48648003P 2003-07-14 2003-07-14
US60/486,480 2003-07-14
US48696003P 2003-07-15 2003-07-15
US60/486,960 2003-07-15
US49357303P 2003-08-08 2003-08-08
US49337003P 2003-08-08 2003-08-08
US60/493,370 2003-08-08
US60/493,573 2003-08-08

Publications (3)

Publication Number Publication Date
WO2004020595A2 WO2004020595A2 (en) 2004-03-11
WO2004020595A8 true WO2004020595A8 (en) 2004-07-15
WO2004020595A3 WO2004020595A3 (en) 2006-05-04

Family

ID=32686486

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/027107 Ceased WO2004020595A2 (en) 2002-08-29 2003-08-28 Novel human polypeptides encoded by polynucleotides

Country Status (1)

Country Link
WO (1) WO2004020595A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
KR101200133B1 (en) 2004-06-01 2012-11-13 제넨테크, 인크. Antibody drug conjugates and methods
ES2579805T3 (en) 2004-09-23 2016-08-16 Genentech, Inc. Antibodies and conjugates engineered with cysteine
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CN101454339A (en) * 2006-05-05 2009-06-10 马斯特里赫特大学/马斯特里赫特心血管研究院 Peptides for use in diagnosing the presence of ruptured atherosclerotic lesions in an individual
US9267946B2 (en) 2009-03-30 2016-02-23 Inserm (Institut National De La Sante Et De La Rec Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
MA34277B1 (en) 2010-04-15 2013-06-01 Spirogen Developments Sarl PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
MX336540B (en) 2010-06-08 2016-01-22 Genentech Inc Cysteine engineered antibodies and conjugates.
ES2544608T3 (en) 2010-11-17 2015-09-02 Genentech, Inc. Antibody and alaninyl-maitansinol conjugates
KR101992502B1 (en) 2011-05-12 2019-06-24 제넨테크, 인크. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
SI2750713T1 (en) 2011-10-14 2016-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
HUE039329T2 (en) 2012-10-12 2018-12-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
DK2906251T3 (en) 2012-10-12 2017-11-20 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22-antibody conjugates
BR112015008174B1 (en) 2012-10-12 2022-12-27 Medimmune Limited PYROLOBENZODIAZEPINE-ANTIBOD CONJUGATES, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATES AND USES THEREOF TO TREAT PROLIFERATIVE DISEASE AND CANCER
KR101986404B1 (en) 2012-10-12 2019-06-07 에이디씨 테라퓨틱스 에스에이 Pyrrolobenzodiazepine - anti-psma antibody conjugates
EP2766048B1 (en) 2012-10-12 2014-12-10 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
ES2660029T3 (en) 2012-10-12 2018-03-20 Medimmune Limited Antibody-pyrrolobenzodiazepine conjugates
JP6340019B2 (en) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
JP6444902B2 (en) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
JP6445519B2 (en) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
CN105873614B (en) 2013-12-16 2020-10-30 基因泰克公司 Peptidomimetic compounds and antibody-drug conjugates thereof
MX2016007826A (en) 2013-12-16 2017-03-31 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof.
BR112016013258A2 (en) 2013-12-16 2018-01-16 Genentech Inc antibody-drug conjugate, pharmaceutical composition, method for treating cancer and kit
CN106687141A (en) 2014-09-10 2017-05-17 麦迪穆有限责任公司 Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
EP3191521A2 (en) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
SG11201702079UA (en) 2014-09-17 2017-04-27 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
NZ731782A (en) 2014-11-25 2023-04-28 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CN107206101B (en) 2014-12-03 2021-06-25 基因泰克公司 Quaternary ammonium compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (en) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド Multiple whole antibody and antibody complex drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
CN109313200B (en) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 Bioanalytical methods for characterizing site-specific antibody-drug conjugates
CN109476648B (en) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 Sevelamer antibody-drug conjugates and methods of use
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
RS61795B1 (en) 2017-02-08 2021-06-30 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
LT3612537T (en) 2017-04-18 2022-10-10 Medimmune Limited Pyrrolobenzodiazepine conjugates
ES2977788T3 (en) 2017-04-20 2024-08-30 Adc Therapeutics Sa Combination therapy with an anti-AXL antibody-drug conjugate
KR102442736B1 (en) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 Dosage regime for administration of anti-CD19 ADCs
WO2019034764A1 (en) 2017-08-18 2019-02-21 Medimmune Limited Pyrrolobenzodiazepine conjugates
KR20200055065A (en) 2017-09-20 2020-05-20 주식회사 피에이치파마 Tylanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
IL282441B2 (en) 2018-10-24 2025-07-01 Hoffmann La Roche Combined chemical influencing factors of decomposition and methods of use
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
KR102351041B1 (en) * 2018-12-19 2022-01-13 한국화학연구원 Cell penetrating Domain derived from human LRRC24 protein
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
ES2967878T3 (en) 2019-03-15 2024-05-06 Medimmune Ltd Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
CN111259667A (en) * 2020-01-16 2020-06-09 上海国民集团健康科技有限公司 Chinese medicine word segmentation algorithm
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
EP4637833A2 (en) 2022-12-23 2025-10-29 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
AU2024257248A1 (en) 2023-04-17 2025-11-06 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6426186B1 (en) * 2000-01-18 2002-07-30 Incyte Genomics, Inc Bone remodeling genes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
WO2004020595A3 (en) 2006-05-04
WO2004020595A2 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2004020595A8 (en) Novel human polypeptides encoded by polynucleotides
WO2004035732A3 (en) Human polypeptides encoded by polynucleotides and methods of their use
WO2002024909A3 (en) Receptor nucleic acids and polypeptides
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
EP1005540A4 (en) Ikk-beta proteins, nucleic acids and methods
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
WO2003020932A1 (en) Novel secretory proteins and dna thereof
WO2003018758A3 (en) Reagents and methods for smooth muscle therapies
PT1373503E (en) Neurotrophic factors
WO2004093804A3 (en) Human polypeptides encoded by polynucleotides and methods of their use
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2004087874A3 (en) Novel nucleic acids and polypeptides
WO2004094651A3 (en) Novel human polypeptides encoded by polynucleotides
MXPA03006218A (en) Type 2 ctokine receptor and nucleic acids encoding same.
WO2004020591A3 (en) Methods of use for novel human polypeptides encoded by polynucleotides
WO2004038003A3 (en) Human polypeptides encoded by polynucleotides and methods of their use
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor
WO2007087053A3 (en) Bmp-7 variant compositions, methods and uses
WO2003055980A3 (en) Il-17 like molecules and uses thereof
WO2004039952A8 (en) Methods of use for novel human polypeptides encoded by polynucleotides
WO2005085280A3 (en) HUMAN cDNA CLONES COMPRISING POLYNUCLEOTIDES ENCODING POLYPEPTIDES AND METHODS OF THEIR USE
WO2004078130A3 (en) Posh interacting proteins and related methods
WO2004039319A3 (en) Novel human polypeptides encoded by polynucleotides
WO2004046310A3 (en) Novel mouse polypeptides encoded by polynucleotides and methods of their use
WO2004089302A3 (en) Posh polypeptides, complexes and related methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 11/2004 UNDER (30) ADD "60/463,732 18 APRIL 2003 (18.04.2003) US; 60/463,700 18 APRIL 2003 (18.04.2003) US; 60/467,230 02 MAY 2003 (02.05.2003) US; 60/467,203 02 MAY 2003 (02.05.2003) US; 60/471,306 19 MAY 2003 (19.05.2003) US; 60/472,420 22 MAY 2003 (22.05.2003) US; 60/476,609 09 JUNE 2003 (09.06.2003) US; 60/485,223 08 JULY 2003 (08.07.2003) US; 60/485,325 08 JULY 2003 (08.07.2003) US; 60/486,480 14 JULY 203 (14.07.2003) US; 60/486,960 15 JULY 2003 (15.07.2003) US; 60/493,573 08 AUGUST 2003 (08.08.2003) US; 60/493,370 08 AUGUST 2003 (08.08.2003) US"

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP